Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Some people to be offered another Covid booster jab

Over 75s and some under 12s are on the list

Wales Online

Elderly and vulnerable to be offered spring Covid booster jab

People aged 75 and over will be offered a vaccination, along with care home residents and anyone aged five and over who is immunosuppressed.

The Independent UK

Former RAA employee Susan Clarke convicted and fined for COVID-19 vaccination fraud

An Adelaide woman who exploited a vulnerable person to have a COVID-19 vaccination in her name to keep her job has been fined nearly $8,000 for her crime, with the sentencing judge describing her conduct as "reprehensible".

ABC News

From analysis to the latest developments in health,
read the most diverse news in one place.

An FDA panel has recommended a 2-dose RSV vaccine for older Americans. Here’s when they might be able to get it

The jabs could be ready as soon as this summer, one expert tells Fortune.

Fortune

Laurence Fox's GB News show struck by Ofcom complaints over Covid pregnancy claims

GB News came under fire from viewers over an interview in which Dr Tina Peers claimed 58% of women suffered a miscarriage during the Pfizer Covid vaccine trial

Daily Mirror

Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It's a market that will be worth up to $10 billion in a decade

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

Fortune

FDA panel narrowly backs Pfizer RSV vaccine for older adults

Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Tribune News Service

1 High-Value Stock to Keep in Your Portfolio Forever

Pfizer (PFE) reported record-breaking revenue and earnings for fiscal 2022. Furthermore, the combination of expected launches and additional pipeline products position the company for continued robust growth through the rest of this decade and beyond. Amid a volatile macro environment, investing in this high-value stock for the long term could…

StockNews.com

Is there a vaccine for RSV or respiratory syncytial virus? After almost 60 years, several come at once

You might not have heard of respiratory syncytial virus, or RSV. But it caused more than 100,000 global deaths in 2019, making it a leading cause of death in children under one year old.

The Conversation

FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccine

The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus vaccine.

Tribune News Service

RSV vaccines for babies, adults on the way. Here’s what could be coming.

Respiratory syncytial virus infects nearly everyone by age 2, usually causing nothing beyond cold symptoms. But it’s also the top cause of hospitalizations among kids under 5.

Chicago Sun-Times

The latest COVID-19 news and case numbers from around the states and territories

Here's a quick wrap of the COVID-19 news and case numbers from each Australian jurisdiction from the past week.

ABC News

3 Bargain Stocks to Buy Before the Crowd Catches On

A resilient economy and sticky inflation could lead Fed officials to hike interest rates higher than anticipated in the central bank’s next meeting. Although markets have been highly volatile amid concerns over the potential rate hikes and other macro headwinds, this has created an attractive opportunity for investors to scoop…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

ABC News

A new bivalent COVID-19 booster rolls out next month. Here's what you need to know about the vaccine

All Australian adults who haven't had a COVID-19 booster or a confirmed case in the past six months are now eligible for an additional shot.

Daily Mirror

Medics told mum cancer symptoms were Covid jab side effects - now she has months to live

Katie Pritchard is having to crowdfund £200,000 for private treatment after she was twice misdiagnosed, being told her symptoms may have been down to the Pfizer vaccine and even being insulted by the suggestion it was an STI

Los Angeles Times

'Sobering': LA's Black, Latino kids under 5 are far behind on COVID-19 vaccinations

LOS ANGELES — Black and Latino children in Los Angeles County younger than 5 have COVID-19 vaccination rates in the single digits, reflecting a broad trend nationwide that has public health experts concerned and seeking ways to boost those figures.

Wales Online

Game of Thrones star Iwan Rheon films in Swansea street transported back to 1994 for new drama Men Up

The film will follow the lives of five ordinary Welshmen as they go through an extraordinary journey which ultimately, and quite accidentally - led to the creation of the erectile dysfunction drug - Viagra

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

Bangkok Post

Seoul donates next-gen Covid jabs

The Republic of Korea has donated over 500,000 doses of the bivalent Pfizer Covid-19 vaccine to Thailand to mark the 65th anniversary of diplomatic relations between the two countries.

StockNews.com

3 Stocks You Won't Have Regrets About Buying in 2023

January’s robust macroeconomic reports indicate that the Fed might raise the interest rates for longer than expected. Also, the dramatic rise in consumer debt in the fourth quarter of 2022 is a red signal for the economy. Hence, fundamentally strong stocks Pfizer (PFE), CVS Health (CVS), and Universal Logistics (ULH)…

Bangkok Post

Govt to roll out new vaccine next month

The Public Health Ministry will begin the roll-out of Pfizer's BA.1 bivalent Covid-19 vaccine next month, according to Dr Thares Krasanairawiwong, chief of the Department of Disease Control (DDC).

Asharq Al-Awsat

Covid Infection Gives Similar Immunity to Vaccination

The protection against Covid-19 from being previously infected lasts at least as long as that offered by vaccination, one of the largest studies conducted on the subject said on Friday. Ten months after getting Covid, people still had an 88 percent lower risk of reinfection, hospitalization and death, according to…

ABC News

Risk of COVID death or hospitalisation 88 per cent lower for those previously infected, study finds

One of the largest studies conducted on COVID immunity finds that previous infections provide protection for as long as vaccination, but experts caution vaccines are still the safer option.

The Independent UK

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

1 … 28 29 30 31

People

Kritika SarmahHer

727 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Public Health Ministry

436 stories

GSK

408 stories

Food and Drug Administration

347 stories

PFE

346 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.